FY2030 Earnings Forecast for Annexon Issued By HC Wainwright

Annexon, Inc. (NASDAQ:ANNX) – HC Wainwright issued their FY2030 earnings per share (EPS) estimates for Annexon in a note issued to investors on Thursday, April 2nd. HC Wainwright analyst A. Ghosh forecasts that the company will post earnings per share of $0.43 for the year. The consensus estimate for Annexon’s current full-year earnings is ($0.96) per share.

Annexon (NASDAQ:ANNX) last released its earnings results on Monday, March 30th. The company reported ($0.28) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.32) by $0.04.

Several other brokerages have also recently commented on ANNX. Chardan Capital reiterated a “buy” rating and issued a $16.00 price target on shares of Annexon in a research note on Friday, March 20th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Annexon in a report on Wednesday, January 21st. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Annexon in a research report on Wednesday, January 14th. Five research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $17.00.

Annexon Stock Performance

ANNX stock opened at $5.50 on Friday. The company has a market capitalization of $657.97 million, a PE ratio of -4.04 and a beta of 1.14. The company’s fifty day moving average price is $5.55 and its 200-day moving average price is $4.57. Annexon has a one year low of $1.28 and a one year high of $7.18.

Insider Activity at Annexon

In other news, EVP Michael Overdorf sold 6,225 shares of the business’s stock in a transaction dated Wednesday, February 18th. The shares were sold at an average price of $5.10, for a total value of $31,747.50. Following the sale, the executive vice president directly owned 124,464 shares in the company, valued at $634,766.40. The trade was a 4.76% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Ted Yednock sold 7,857 shares of the company’s stock in a transaction dated Wednesday, February 18th. The shares were sold at an average price of $5.11, for a total transaction of $40,149.27. Following the sale, the executive vice president owned 97,227 shares in the company, valued at $496,829.97. This represents a 7.48% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 32,513 shares of company stock valued at $165,973 over the last quarter. 11.87% of the stock is currently owned by insiders.

Institutional Trading of Annexon

Institutional investors have recently bought and sold shares of the stock. CIBC Bancorp USA Inc. bought a new position in Annexon during the third quarter valued at $31,000. Engineers Gate Manager LP purchased a new position in shares of Annexon during the 2nd quarter worth about $32,000. SG Americas Securities LLC purchased a new position in shares of Annexon during the 3rd quarter worth about $34,000. Mirae Asset Global Investments Co. Ltd. grew its holdings in Annexon by 65.6% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,033 shares of the company’s stock valued at $35,000 after purchasing an additional 2,785 shares during the last quarter. Finally, Savant Capital LLC bought a new position in Annexon during the 3rd quarter valued at about $40,000.

Annexon Company Profile

Annexon Inc is a clinical-stage biotechnology company focused on the discovery and development of complement-targeted therapies for patients with neurodegenerative and neuroimmune diseases. The company’s research platform centers on the inhibition of the C1 complex, a key initiator of the classical complement pathway implicated in several rare and life-threatening disorders. By selectively targeting upstream complement activation, Annexon aims to prevent the aberrant immune-mediated damage that characterizes conditions such as Guillain-Barré syndrome (GBS) and autoimmune neuropathies.

At the core of Annexon’s pipeline is ANX005, a humanized monoclonal antibody directed against the C1q subcomponent, currently in Phase 2 clinical trials for acute GBS and chronic neurodegenerative indications.